The Canadian Agency for Drugs and Technologies in Health (CADTH) recommends FSL reimbursement for T1DM and T2DM patients requiring multiple daily insulins injections and experiencing recurrent hypoglycemia, despite frequent SMBG and efforts to optimize insulin management [16]. The gene discussed is INS; the disease is type 2 diabetes mellitus.